Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses unmet needs facing patients with colorectal cancer (CRC). 

According to Alberts, an unmet need in many advanced malignancies is prevention. Many cancers can be prevented with the use of vaccines, therefore, further studies are needed to develop new vaccines for different cancers types, says Alberts. 

Videos

Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses unmet needs facing patients with colorectal cancer (CRC).

Dr. Alberts on Unmet Needs in CRC

Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses recent updates in liver cancer.

Until the approval of regorafenib (Stivarga) in 2017, the only FDA-approved agent for the treatment of hepatocellular carcinoma (HCC) was sorafenib (Nexavar).

At the 2017 ASCO Annual Meeting, data on lenvatinib (Lenvima) were presented, showing comparable results to sorafenib and is likely to be approved for patients with HCC, says Alberts.

Steven R. Alberts, MD, professor of oncology in the College of Medicine, Mayo Clinic, discusses recent updates in liver cancer.
 

Steven R. Alberts, MD

Articles

Dr. Alberts on Unmet Needs in CRC

Dr. Alberts Discusses Updates in Liver Cancer